{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:38:23Z","timestamp":1792478303137,"version":"4.5.0"},"reference-count":75,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.1001\/jamaoncol.2018.1915","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T12:30:57Z","timestamp":1529584257000},"page":"1413","source":"Crossref","is-referenced-by-count":89,"title":["Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia"],"prefix":"10.1001","volume":"4","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hon","family":"Pui","sequence":"additional","affiliation":[{"name":"Department of Oncology, St Jude Children\u2019s Research Hospital, Memphis, Tennessee"},{"name":"Department of Pathology, St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"27","key":"crv180002r2","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration.","volume":"33","author":"Pui","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"crv180002r3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"key":"crv180002r4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ebiom.2016.04.038","article-title":"Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia.","volume":"8","author":"Liu","year":"2016","journal-title":"EBioMedicine"},{"issue":"26","key":"crv180002r5","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","article-title":"Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.","volume":"124","author":"Hoelzer","year":"2014","journal-title":"Blood"},{"issue":"7","key":"crv180002r6","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"10036","key":"crv180002r7","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","article-title":"Rituximab and dose-dense chemotherapy for adults with Burkitt\u2019s lymphoma: a randomised, controlled, open-label, phase 3 trial.","volume":"387","author":"Ribrag","year":"2016","journal-title":"Lancet"},{"issue":"24","key":"crv180002r8","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"crv180002r9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia.","volume":"375","author":"Maury","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"crv180002r10","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"issue":"12","key":"crv180002r11","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","article-title":"First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"issue":"15","key":"crv180002r12","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.","volume":"16","author":"Jabbour","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"crv180002r13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ajh.v93.1","article-title":"Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.","volume":"93","author":"Abaza","year":"2018","journal-title":"Am J Hematol"},{"issue":"23","key":"crv180002r14","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1200\/JCO.2016.71.8585","article-title":"Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a Group for Research on Adult Acute Lymphoblastic Leukemia study.","volume":"35","author":"Bond","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15","key":"crv180002r15","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","article-title":"Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype.","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"issue":"20","key":"crv180002r16","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"5","key":"crv180002r17","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"crv180002r18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol"},{"issue":"11","key":"crv180002r19","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"crv180002r20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.clml.2017.03.299","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia.","volume":"17","author":"Pui","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"crv180002r21","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood-2014-09-595744","article-title":"A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.","volume":"125","author":"Perez-Andreu","year":"2015","journal-title":"Blood"},{"issue":"11","key":"crv180002r22","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat Genet"},{"issue":"2","key":"crv180002r23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"issue":"1","key":"crv180002r24","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1073\/pnas.0911726107","article-title":"Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.","volume":"107","author":"Yoda","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"27","key":"crv180002r25","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1200\/JCO.2014.55.4105","article-title":"Outcomes of children with BCR-ABL1\u2013like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.","volume":"32","author":"Roberts","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"crv180002r26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"issue":"3","key":"crv180002r27","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/cncr.v123.3","article-title":"Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.","volume":"123","author":"Issa","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"crv180002r28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/ng.2532","article-title":"The genomic landscape of hypodiploid acute lymphoblastic leukemia.","volume":"45","author":"Holmfeldt","year":"2013","journal-title":"Nat Genet"},{"issue":"6","key":"crv180002r29","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/gcc.v53.6","article-title":"Acute lymphoblastic leukemia with low hypodiploid\/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%.","volume":"53","author":"M\u00fchlbacher","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"crv180002r30","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3324\/haematol.2014.118588","article-title":"Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"issue":"22","key":"crv180002r31","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1200\/JCO.2010.28.1287","article-title":"Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09\/00.","volume":"28","author":"Bassan","year":"2010","journal-title":"J Clin Oncol"},{"issue":"31","key":"crv180002r32","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children\u2019s Oncology Group study.","volume":"27","author":"Schultz","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"crv180002r33","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","article-title":"Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).","volume":"108","author":"Wassmann","year":"2006","journal-title":"Blood"},{"issue":"23","key":"crv180002r34","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1002\/cncr.29646","article-title":"Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.","volume":"121","author":"Ravandi","year":"2015","journal-title":"Cancer"},{"issue":"3","key":"crv180002r35","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","article-title":"US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL.","volume":"1","author":"Ravandi","year":"2016","journal-title":"Blood Adv"},{"issue":"6","key":"crv180002r36","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood"},{"issue":"23","key":"crv180002r37","doi-asserted-by":"crossref","first-page":"abstr 81","DOI":"10.1182\/blood.V126.23.81.81","article-title":"Multicenter total therapy Gimema LAL 1509 for de novo adult Ph+ acute lymphoblastic leukemia (ALL) patients. Updated results and refined genetic-based prognostic stratification.","volume":"126","author":"Chiaretti","year":"2015","journal-title":"Blood"},{"key":"crv180002r39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1182\/blood.V130.Suppl_1.99.99","article-title":"First report of the Gimema LAL1811 phase II prospective study of the combination of steroids with ponatinib as frontline therapy of elderly or unfit patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.","volume":"130","author":"Martinelli","year":"2017","journal-title":"Blood"},{"issue":"23","key":"crv180002r40","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1002\/cncr.v122.23","article-title":"Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis.","volume":"122","author":"Sasaki","year":"2016","journal-title":"Cancer"},{"issue":"4","key":"crv180002r41","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","article-title":"Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.","volume":"128","author":"Short","year":"2016","journal-title":"Blood"},{"issue":"5","key":"crv180002r42","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? a comparison of Children\u2019s Cancer Group and Cancer and Leukemia Group B studies.","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"issue":"21","key":"crv180002r43","doi-asserted-by":"crossref","first-page":"abstr 796","DOI":"10.1182\/blood.V124.21.796.796","article-title":"Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of US Intergroup trial C10403.","volume":"124","author":"Stock","year":"2014","journal-title":"Blood"},{"issue":"6","key":"crv180002r44","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"crv180002r45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/leu.2016.219","article-title":"Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial.","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"crv180002r46","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/ajh.24419","article-title":"Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M\u00fcnster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.","volume":"91","author":"Rytting","year":"2016","journal-title":"Am J Hematol"},{"issue":"10036","key":"crv180002r47","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/S0140-6736(16)00164-1","article-title":"Chemoimmunotherapy as a new standard of care for Burkitt leukaemia\/lymphoma.","volume":"387","author":"Jabbour","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"crv180002r48","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.blre.2011.08.001","article-title":"Chemoimmunotherapy in acute lymphoblastic leukemia.","volume":"26","author":"Hoelzer","year":"2012","journal-title":"Blood Rev"},{"issue":"5","key":"crv180002r49","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.hoc.2009.07.008","article-title":"Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.","volume":"23","author":"DeAngelo","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"issue":"8","key":"crv180002r50","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1002\/cncr.v113:8","article-title":"Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.","volume":"113","author":"O\u2019Brien","year":"2008","journal-title":"Cancer"},{"key":"crv180002r51","doi-asserted-by":"crossref","first-page":"abstr 1493","DOI":"10.1182\/blood.V120.21.1493.1493","article-title":"Moderate intensive chemotherapy including CNS-prophylaxis with liposomal cytarabine is feasible and effective in older patients with Ph-negative acute lymphoblastic leukemia (ALL): results of a prospective trial from the German multicenter study group for adult ALL (GMALL).","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"crv180002r52","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood.V128.22.3981.3981","article-title":"Patient characteristics and treatment patterns in elderly patients newly diagnosed with acute lymphoblastic leukemia (ALL) using 100% Medicare ALL data.","volume":"128","author":"Li","year":"2016","journal-title":"Blood"},{"issue":"13","key":"crv180002r53","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1182\/blood-2016-11-749507","article-title":"Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis.","volume":"129","author":"Geyer","year":"2017","journal-title":"Blood"},{"issue":"2","key":"crv180002r54","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"crv180002r55","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1470-2045(15)70082-3","article-title":"Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.","volume":"16","author":"Pui","year":"2015","journal-title":"Lancet Oncol"},{"issue":"15","key":"crv180002r56","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","article-title":"Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.","volume":"32","author":"Ribera","year":"2014","journal-title":"J Clin Oncol"},{"issue":"16","key":"crv180002r57","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia.","volume":"125","author":"Dh\u00e9din","year":"2015","journal-title":"Blood"},{"issue":"7","key":"crv180002r58","doi-asserted-by":"publisher","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis.","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"24","key":"crv180002r59","doi-asserted-by":"publisher","first-page":"5568","DOI":"10.1002\/cncr.v116:24","article-title":"Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration.","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"issue":"14","key":"crv180002r60","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"1","key":"crv180002r61","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"crv180002r62","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia.","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"crv180002r63","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study.","volume":"35","author":"Martinelli","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"crv180002r64","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.clml.2017.08.101","article-title":"Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia.","volume":"17","author":"Assi","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"15","key":"crv180002r65","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"issue":"15","key":"crv180002r66","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","article-title":"Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study.","volume":"1","author":"DeAngelo","year":"2017","journal-title":"Blood Adv"},{"issue":"8","key":"crv180002r67","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia.","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"crv180002r68","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2017.2380","article-title":"Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed\/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial.","volume":"4","author":"Jabbour","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"crv180002r69","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/cncr.30264","article-title":"Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia.","volume":"123","author":"Jabbour","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"crv180002r70","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrclinonc.2015.187","article-title":"Novel immunotherapies in lymphoid malignancies.","volume":"13","author":"Batlevi","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"crv180002r71","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V128.22.2801.2801","article-title":"Efficacy and safety of CTL019 in the first US phase II multicenter trial in pediatric relapsed\/refractory acute lymphoblastic leukemia: results of an interim analysis.","volume":"128","author":"Maude","year":"2016","journal-title":"Blood"},{"issue":"5","key":"crv180002r72","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"crv180002r73","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia.","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"crv180002r74","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"crv180002r75","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V130.Suppl_1.887.887","article-title":"Preliminary results of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a first-in-human trial (CALM) in adult patients with CD19+ relapsed\/refractory B-cell acute lymphoblastic leukemia.","volume":"130","author":"Graham","year":"2017","journal-title":"Blood"},{"key":"crv180002r38","author":"Short"},{"key":"crv180002r1","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Populations - Total U.S. (1969-2016) <Katrina\/Rita Adjustment> - Linked to County Attributes - Total U.S., 1969-2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released November 2017. https:\/\/seer.cancer.gov. Accessed December 21, 2017."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/edhub.ama-assn.org\/journals\/jamaoncology\/fullarticle\/2685652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T23:41:39Z","timestamp":1661470899000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.1915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":75,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.1915","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10,1]]}}}